Market Overview

UPDATE: BMO Capital Downgrades Pfizer

Related PFE
Pfizer And Western Oncolytics Reach Immuno-Oncology Research Collaboration
18 Biggest Mid-Day Gainers For Wednesday
Biotech Forum Daily Digest: Biotech Tries To Break Through Upward Resistance Levels (Seeking Alpha)

In a report released Monday, BMO Capital analyst Alex Arfaei downgraded Pfizer (NYSE: PFE) from Outperform to Market Perform while reducing its price target from $34 to $31.

Analysts at BMO stated Pfizer has "limited growth prospects." Pfizer's new drug releases do not outweigh its mature franchises heavily declining dividend; backpacks create some short-term support, but not enough for growth maintenance.

Latest Ratings for PFE

Jul 2016JefferiesMaintainsBuy
Jun 2016JefferiesMaintainsBuy
Jun 2016JefferiesMaintainsBuy

View More Analyst Ratings for PFE
View the Latest Analyst Ratings

Posted-In: Alex Arfaei BMO CapitalDowngrades Price Target Analyst Ratings


Related Articles (PFE)

View Comments and Join the Discussion!